Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Sunday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

NASDAQ ADXS opened at $0.03 on Friday. The company has a 50-day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.97. The firm has a market cap of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.63.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.